This article was originally published in SRA
US FDA rules on authorised generic deals
You may also be interested in...
Roche hopes that its investigational drug satralizumab for neuromyelitis optica spectrum disorder will win EU approval in the second half of 2020.
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
The US Centers for Disease Control and Prevention is reformulating a reagent in a batch of COVID-19 tests due to inconsistent performance. See what CDC official Nancy Messonier had to say about it.